The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice

被引：0

作者：

Z.-D. Yang

M. Chen

R. Wu

M. McDuffie

J.-L. Nadler

机构：

[1] Division of Endocrinology and Metabolism,

[2] Department of Internal Medicine,undefined

[3] University of Virginia,undefined

[4] Charlottesville,undefined

[5] VA 22908-1405,undefined

[6] Division of Endocrinology and Metabolism,undefined

[7] Department of Internal Medicine,undefined

[8] Department of Microbiology,undefined

[9] University of Virginia,undefined

[10] Charlottesville,undefined

[11] Virginia,undefined

来源：

Diabetologia | 2002年 / 45卷

关键词：

Lisofylline NOD mice macrophage IL-1β insulitis Type I diabetes mellitus;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Aims/hypothesis. Pro-inflammatory cytokines are increased during the active stages of Type I (insulin-dependent) diabetes mellitus. The aim of this study was to investigate the applicability of using a new anti-inflammatory compound, Lisofylline, to prevent diabetes in non-obese diabetic (NOD) mice. Lisofylline has previously been shown to block Th1 cell differentiation and to reduce IL-1β-induced dysfunction in rat islets.

引用

页码：1307 / 1314

页数：7